InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of orofacial pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is based in Vancouver, Canada.
IPO Year:
Exchange: NASDAQ
Website: inmedpharma.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/29/2021 | $6.00 | Buy | HC Wainwright & Co. |
PRE 14A - InMed Pharmaceuticals Inc. (0001728328) (Filer)
8-K - InMed Pharmaceuticals Inc. (0001728328) (Filer)
SCHEDULE 13G/A - InMed Pharmaceuticals Inc. (0001728328) (Subject)
8-K - InMed Pharmaceuticals Inc. (0001728328) (Filer)
8-K - InMed Pharmaceuticals Inc. (0001728328) (Filer)
10-Q - InMed Pharmaceuticals Inc. (0001728328) (Filer)
8-K - InMed Pharmaceuticals Inc. (0001728328) (Filer)
8-K - InMed Pharmaceuticals Inc. (0001728328) (Filer)
8-K - InMed Pharmaceuticals Inc. (0001728328) (Filer)
SCHEDULE 13G/A - InMed Pharmaceuticals Inc. (0001728328) (Subject)
SC 13G/A - InMed Pharmaceuticals Inc. (0001728328) (Subject)
SC 13G - InMed Pharmaceuticals Inc. (0001728328) (Subject)
SC 13G/A - InMed Pharmaceuticals Inc. (0001728328) (Subject)
SC 13G - InMed Pharmaceuticals Inc. (0001728328) (Subject)
SC 13G/A - InMed Pharmaceuticals Inc. (0001728328) (Subject)
SC 13G - InMed Pharmaceuticals Inc. (0001728328) (Subject)
VANCOUVER, British Columbia, Dec. 12, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ:INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today announces the Company has entered into a service contract (the "Contract") with Brio Financial Group ("Brio") to provide senior financial leadership and bookkeeping services. Pursuant to the Contract, Mr. Jonathan Tegge, a member of Brio, will assume the role of Interim Chief Financial Officer for the Company effective December 12, 2022. Brio is a financial and management consulting group based in Bridgewater, New Jersey. The firm provid
VANCOUVER, British Columbia, Aug. 09, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ:INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, is pleased to announce the appointment of Nicole Lemerond to its Board of Directors, effective immediately. Nicole Lemerond is a financial executive with over 25 years of experience in investment management, private equity, investment banking and leveraged finance. She has significant experience executing complex transactions, managing diligence processes, raising capital and structuring balance sheets. Throughout her career, Ms. Lemerond has worked with public
VANCOUVER, British Columbia, July 18, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ:INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today announces Michael Woudenberg has been appointed Chief Operating Officer of the Company, overseeing all day-to-day operations. Mr. Woudenberg was previously Senior Vice President of Chemistry, Manufacturing and Controls. Mike has been an integral part of the executive team for the last four years, supporting multiple functions within the organisation. Prior to joining InMed, Mike had over 20 years of successful drug development, process engineering, GMP manufa
VANCOUVER, British Columbia, Feb. 15, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ:INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, is pleased to announce the appointment of Gerard (Jerry) P. Griffin III as Vice President of Sales and Marketing at BayMedica, a wholly owned subsidiary of InMed. Mr. Griffin will oversee the commercialization of BayMedica's health and wellness business including the existing products and the launch of new rare cannabinoid products. Mr. Griffin has a wealth of experience across various markets and with numerous cannabinoid products, and a proven track record as a s
4 - InMed Pharmaceuticals Inc. (0001728328) (Issuer)
4 - InMed Pharmaceuticals Inc. (0001728328) (Issuer)
HC Wainwright & Co. initiated coverage of InMed Pharmaceuticals with a rating of Buy and set a new price target of $6.00
Roth Capital reiterated coverage of InMed Pharmaceuticals with a rating of Buy and set a new price target of $11.50 from $12.00 previously
4 - InMed Pharmaceuticals Inc. (0001728328) (Issuer)
4 - InMed Pharmaceuticals Inc. (0001728328) (Issuer)
4 - InMed Pharmaceuticals Inc. (0001728328) (Issuer)
4 - InMed Pharmaceuticals Inc. (0001728328) (Issuer)
4 - InMed Pharmaceuticals Inc. (0001728328) (Issuer)
4 - InMed Pharmaceuticals Inc. (0001728328) (Issuer)
4 - InMed Pharmaceuticals Inc. (0001728328) (Issuer)
4 - InMed Pharmaceuticals Inc. (0001728328) (Issuer)
4 - InMed Pharmaceuticals Inc. (0001728328) (Issuer)
4 - InMed Pharmaceuticals Inc. (0001728328) (Issuer)
MIAMI, June 12, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 72nd Emerging Growth Conference on June 12 & 13, 2024. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Sponsors:QuoteMedia - Keep Investors Informed with Dynamic Plug and Play IR Solutions(844) 485-8200Sales@QuoteMed
MIAMI, June 11, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 72nd Emerging Growth Conference on June 12 & 13, 2024. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Sponsors:QuoteMedia - Keep Investors Informed with Dynamic Plug and Play IR Solutions(844) 48
An exploratory clinical evaluation of the Phase 2 clinical trial data showed a positive indication of enhanced anti-itch activity for INM-755 cannabinol ("CBN") cream versus the control cream alone.The results for non-wound itch were not statistically significant in favor of INM-755 CBN cream due, in part, to the clinically important anti-itch effect of the underlying control cream.INM-755 CBN cream demonstrated a favorable safety and tolerability profile.InMed will pursue strategic partnership opportunities for INM-755 in epidermolysis bullosa ("EB") and other itch-related skin conditions.Vancouver, British Columbia--(Newsfile Corp. - June 22, 2023) - InMed Pharmaceuticals Inc. (NASDAQ:INM)
Vancouver, British Columbia--(Newsfile Corp. - June 1, 2023) - InMed Pharmaceuticals Inc. (NASDAQ:INM) ("InMed" or the "Company"), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, today announced that results from a neurodegenerative disease study was presented in a scientific poster at the Canadian Neuroscience Meeting in Montreal from May 28-31, 2023.The InMed sponsored research, entitled "Cannabinoids modulate cytotoxicity and neuritogenesis in Amyloid-beta-treated neuronal cells", demonstrated the ability of a specific rare cannabinoid ("pCBx") in InMed's 900 Series library of potential candidates that
Vancouver, British Columbia--(Newsfile Corp. - May 24, 2023) - InMed Pharmaceuticals Inc. (NASQDAQ: INM) ("InMed" or the "Company"), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, today announce that the Company's executive team will be participating in the upcoming virtual investor events:Tribe Public WebinarDate: May 31, 2023Time: 12:00 PM ETRegistration: https://us06web.zoom.us/webinar/register/WN_6ZYkEADVSPOFd3g68IzQsw#/registrationEric A. Adams, CEO of InMed, and Jerry Griffin, VP, Sales and Marketing of BayMedica, will co-host a presentation event titled, "Addressing The Increasing Demand For Rare
Vancouver, British Columbia--(Newsfile Corp. - May 18, 2023) - InMed Pharmaceuticals Inc. (NASDAQ:INM) ("InMed" or the "Company"), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, today announce Eric A. Adams, CEO of InMed, will be participating in the Water Tower Research Fireside Chat Series on May 23, 2023, at 1:00 pm ET.This event is open access for all investors to participate. Topics will include:An overview of InMed's pharmaceutical development pipelineThe BayMedica subsidiary and its importance to InMed's growth Upcoming catalysts for the CompanyInterested parties can register for the event at the
Completed enrollment in Phase 2 Clinical Trial; data readout expected during calendar 3Q 2023120% quarter-over-quarter revenue growth in the commercial BayMedica subsidiaryPublished a peer-reviewed study showing the anti-inflammatory potential of rare cannabinoidsVancouver, British Columbia--(Newsfile Corp. - May 15, 2023) - InMed Pharmaceuticals Inc. (NASDAQ:INM) ("InMed" or the "Company"), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, today announced financial results for the third quarter of the fiscal year 2023 ("FY 3Q23") which ended March 31, 2023. The Company’s full financial statements and relat
Marks the first time a Phase 2 trial has studied a cannabinol (CBN) formulation as a treatment option for any diseaseData expected to be released in early calendar Q3 2023Vancouver, British Columbia--(Newsfile Corp. - March 28, 2023) - InMed Pharmaceuticals Inc. (NASDAQ:INM) ("InMed" or the "Company"), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today announced it has concluded enrollment of its Phase 2 clinical trial using investigational drug INM-755 cannabinol ("CBN") cream for the treatment of patients with epidermolysis bullosa ("EB"), a rare genetic skin disease.The Phase 2 study, called INM-755-201-EB, enrolled 1
Supports the therapeutic potential of rare cannabinoids in inflammatory skin conditions such as atopic dermatitis, psoriasis, pruritus, and acneFurther demonstrates the anti-inflammatory effects of CBC, THCV, CBG and CBGADetails possible mechanisms of action on how rare cannabinoids can interact with specific skin-related endocannabinoid receptorsVancouver, British Columbia--(Newsfile Corp. - March 13, 2023) - InMed Pharmaceuticals Inc. (NASDAQ:INM) ("InMed" or the "Company"), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today announced that a peer-reviewed scientific study entitled "Rare phytocannabinoids exert anti-inf
MIAMI, March 07, 2023 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 51st Emerging Growth Conference on March 8, 2023. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the conference here. Submit Questions for any of the presenting companies to: [email protected] March 8, 2023, Schedule: (Eastern Time) For updates, follow us on Twitter 9:15Virtual Lobby opens.Register for the Conference. If you already regist
VANCOUVER, British Columbia, Sept. 19, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ:INM), a leader in the research, development and manufacturing of rare cannabinoids, will report financial results on Friday, September 23, 2022 for the fiscal year ended June 30, 2022. Conference Call & Webcast:Friday, September 23, 2022, at 10:00 AM Pacific Time, 01:00 PM Eastern TimeRegistration Link: https://register.vevent.com/register/BIa76ceda464264b3cae0b5ddb6e76a511Webcast Link: https://edge.media-server.com/mmc/p/cnawzqhu(Webcast replay available for 12 months) To access the call by phone, please go to the registration link, and you will be provided w
Completed acquisition of BayMedica, a rare cannabinoid manufacturing and commercialization company in the health and wellness sectorStrengthened IP with patent filing for use of rare cannabinoids for the treatment of neurodegenerative diseasesCommercial rollout of an additional rare cannabinoid, CBT- first of several rare cannabinoid launches planned for the first half of 2022Advanced the pharmaceutical drug development programs in EB, glaucoma and neurodegenerative diseases VANCOUVER, British Columbia, Feb. 14, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ:INM), a leader in the development, manufacturing and commercialization of rare cannabinoids,
VANCOUVER, British Columbia, Feb. 10, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ:INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, will report financial results on Tuesday, February 15, 2022 for the second quarter of fiscal year 2022, ending December 31, 2021. Conference Call & Webcast*:Tuesday, February 15, 2022, at 11:00 AM Pacific Time, 02:00 PM Eastern TimeUS/CANADA Participant Toll-Free Dial-In Number: +1 (855) 605-1745US/CANADA Participant International Dial-In Number: +1 (914) 987-7959Conference ID: 8645175Webcast: https://edge.media-server.com/mmc/p/sa6ykfmv (*Webcast replay available
VANCOUVER, British Columbia, Sept. 17, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ:INM), a leader in the manufacturing and clinical development of rare cannabinoids, will report financial results for the fiscal year ended June 30, 2021, on Friday, September 24, 2021. Conference Call & Webcast*:Friday, September 24, 2021, at 8:00 AM Pacific Time, 11:00 AM Eastern TimeUS/CANADA Participant Toll-Free Dial-In Number: +1 (855) 605-1745US/CANADA Participant International Dial-In Number: +1 (914) 987-7959Conference ID: 9373618Webcast: https://edge.media-server.com/mmc/p/ny89uo2r(*Webcast replay available for 90 days) The Company's full financial statem